Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Chloroquin | Research

Icariin synergizes therapeutic effect of dexamethasone on adriamycin-induced nephrotic syndrome

Authors: Juan Lv, Guozhong Xue, Yunxia Zhang, Xinbin Wang, Enlai Dai

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Glomerular damage is a common clinical indicator of nephrotic syndrome. High-dose hormone treatment often leads to hormone resistance in patients. How to avoid resistance and improve the efficiency of hormone therapy draws much attention to clinicians.

Methods

Adriamycin (ADR) was used to induce nephropathy model in SD rats. The rats were treated with dexamethasone (DEX), icariin (ICA), and DEX + ICA combination therapy. The changes in urinary protein (UP), urea nitrogen (BUN), and serum creatinine (SCR) contents in rats were detected by enzyme-linked immunosorbent assay (ELISA), and the degree of pathological injury and the expression level of podocin were detected by HE staining and immunohistochemistry, to test the success of the model and the therapeutic effects of three different ways. The effect of treatments on podocytes autophagy was evaluated via transfection of mRFP-GFP-LC3 tandem adenovirus in vitro.

Results

The contents of UP, SCR, and BUN were significantly increased, the glomerulus was seriously damaged, and the expression of Nephrosis2 (NPHS2) was significantly decreased in the ADR-induced nephrotic syndrome rat model compared to that of the control group. DEX, ICA, and the DEX + ICA combined treatment significantly alleviated these above changes induced by ADR. The combined treatment of DEX + ICA exhibited better outcome than single treatment. The combined treatment also restored the podocyte autophagy, increased the expression of microtubule-associated protein light-chain 3II (LC3II), and reduced the expression of p62 in vitro. The combined treatment protects podocytes by mediating the PI3K/AKT/mTOR (rapamycin complex) signaling pathway.

Conclusion

ICA enhances the therapeutic effect of DEX on the nephrotic syndrome.

GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–33.CrossRef

Wang CS, Greenbaum LA. Nephrotic syndrome. Pediatr Clin North Am. 2019;66(1):73–85.CrossRef

Kveder R, Kajtna-Koselj M, Rott T, Bren AF. Nephrotic syndrome in patients with diabetes mellitus is not always associated with diabetic nephropathy. Nephrol Dial Transplant. 2001;16(Suppl 6):86–7.CrossRef

Bonillafelix M, Parra C, Dajani T, Ferris M, Al E. Idiopathic nephrotic syndrome in children. Indian J Pediatr. 1982;49(1):29–39.CrossRef

Campbell KN, Tumlin JA. Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol. 2018;47(1):14–29.CrossRef

Mallipattu SK, HE JC. The podocyte as a direct target for treatment of glomerular disease? Am J Physiol Renal Physiol. 2016;311(1):F46–51.CrossRef

Song L, Chen X, Mi L, Liu C, Zhu S, Yang T, Luo X, Zhang Q, Lu H, Liang X. Icariin-induced inhibition of SIRT6/NF-κB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer. Cancer Sci. 2020;111(11):4242–56.CrossRef

Qi S, He J, Zheng H, Chen C, Lan S. Icariin prevents diabetes-induced bone loss in rats by reducing blood glucose and suppressing bone turnover. Molecules. 2019;24(10):1871–84.CrossRef

Cao LH, Qiao JY, Huang HY, Fang XY, Zhang R, Miao MS, Li XM. PI3K-AKT signaling activation and icariin: the potential effects on the perimenopausal depression-like rat model. Molecules. 2019;24(20):3700–17.CrossRef

10.

Angeloni C, Barbalace MC, Hrelia S. Icariin and its metabolites as potential protective phytochemicals against Alzheimer’s disease. Front Pharmacol. 2019;10(01):271–8.CrossRef

11.

Li X, Wang YX, Shi P, Liu YP, Li T, Liu SQ, Wang CJ, Wang LX, Cao Y. Icariin treatment reduces blood glucose levels in type 2 diabetic rats and protects pancreatic function. Exp Ther Med. 2020;19(4):2690–6.

12.

Qiao C, Wang H, Song Z, Ding Y, Tao J, Aa J, Ding X. Icariin attenuates diabetic cardiomyopathy and downregulates extracellular matrix proteins in heart tissue of type 2 diabetic rats. Pharmacology. 2020;105(9–10):576–85.CrossRef

13.

Artunc F, Nasir O, Amann K, Boini KM, Häring HU, Risler T, Lang F. Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome. Am J Physiol Renal Physiol. 2008;295(6):F1624–34.CrossRef

14.

Fan HY, Wang XK, Li X, Ji K, Du SH, Liu Y, Kong LL, Xu JC, Yang GQ, Chen DQ, Qi D. Curcumin, as a pleiotropic agent, improves doxorubicin-induced nephrotic syndrome in rats. J Ethnopharmacol. 2020;250(01):112502–40.CrossRef

15.

Li F, Mao X, Zhuang Q, Zhao Z, Zhang Z, Wu H. Inhibiting 4E-BP1 re-activation represses podocyte cell cycle re-entry and apoptosis induced by adriamycin. Cell Death Dis. 2019;10(3):241.CrossRef

16.

Sutariya B, Saraf M. α-asarone reduce proteinuria by restoring antioxidant enzymes activities and regulating necrosis factor κB signaling pathway in adriamycin-induced nephrotic syndrome. Biomed Pharmacother. 2018;98(01):318–24.CrossRef

17.

Ma P, Zhang S, Su X, Qiu G, Wu Z. Protective effects of icariin on cisplatin-induced acute renal injury in mice. Am J Transl Res. 2015;7(10):2105–14.

18.

Guo Y, Wang L, Ma R, Mu Q, Yu N, Zhang Y, Tang Y, Li Y, Jiang G, Zhao D, Mo F, Gao S, Yang M, Kan F, Ma Q, Fu M, Zhang D. JiangTang XiaoKe granule attenuates cathepsin K expression and improves IGF-1 expression in the bone of high fat diet induced KK-Ay diabetic mice. Life Sci. 2016;148(01):24–30.CrossRef

19.

Paller MS, Neumann TV. Reactive oxygen species and rat renal epithelial cells during hypoxia and reoxygenation. Kidney Int. 1991;40(6):1041–9.CrossRef

20.

Liu WJ, Luo MN, Tan J, Chen W, Huang LZ, Yang C, Pan Q, Li B, Liu HF. Autophagy activation reduces renal tubular injury induced by urinary proteins. Autophagy. 2014;10(2):243–56.CrossRef

21.

Bork T, Liang W, Yamahara K, Lee P, Tian Z, Liu S, Schell C, Thedieck K, Hartleben B, Patel K, Tharaux PL, Lenoir O, Huber TB. Podocytes maintain high basal levels of autophagy independent of mtor signaling. Autophagy. 2020;16(11):1932–48.CrossRef

22.

Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. Mo Med. 2011;108(1):33–6.

23.

Liang T, Qi C, Lai Y, Xie J, Wang H, Zhang L, Lin T, Jv M, Li J, Wang Y, Zhang Y, Chen Z, Qiu X, Li R, Li Z, Ye Z, Liu S, Liang X, Shi W, Wang W. HDAC6-mediated α-tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy. J Cell Mol Med. 2020;24(19):11558–72.CrossRef

24.

Yi M, Zhang L, Liu Y, Livingston MJ, Chen JK, Nahman NS Jr, Liu F, Dong Z. Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy. Am J Physiol Renal Physiol. 2017;313(1):F74–84.CrossRef

25.

Yang F, Qu Q, Zhao C, Liu X, Yang P, Li Z, Han L, Shi X. Paecilomyces cicadae-fermented Radix astragali activates podocyte autophagy by attenuating PI3K/AKT/mTOR pathways to protect against diabetic nephropathy in mice. Biomed Pharmacother. 2020;129(01):110479–90.CrossRef

26.

Liu M, Qiao Z, Zhang Y, Zhan P, Yi F. Histone deacetylases take center stage on regulation of podocyte function. Kidney Dis. 2020;6(4):236–46.CrossRef

27.

Hou B, Li Y, Li X, Zhang C, Zhao Z, Chen Q, Zhang N, Li H. HGF protected against diabetic nephropathy via autophagy-lysosome pathway in podocyte by modulating PI3K/Akt-GSK3β-TFEB axis. Cell Signal. 2020;75(01):109744–67.CrossRef

28.

Fan H, Zhang W. Overexpression of linc 4930556M19Rik suppresses high glucose-triggered podocyte apoptosis, fibrosis and inflammation via the miR-27a-3p/metalloproteinase 3 (TIMP3) axis in diabetic nephropathy. Med Sci Monit. 2020;26(01):925361–71.

29.

Wang X, Liu Q, Kong D, Long Z, Guo Y, Wang S, et al. Down-regulation of SETD6 protects podocyte against high glucose and palmitic acid-induced apoptosis, and mitochondrial dysfunction via activating Nrf2-Keap1 signaling pathway in diabetic nephropathy. J Mol Histol. 2020;51(5):549–58.CrossRef

30.

Scicchitano M, Carresi C, Nucera S, Ruga S, Maiuolo J, Macrì R, Scarano F, Bosco F, Mollace R, Cardamone A, Coppoletta AR, Guarnieri L, Zito MC, Bava I, Cariati L, Greco M, Foti DP, Palma E, Gliozzi M, Musolino V, Mollace V. Icariin protects h9c2 rat cardiomyoblasts from doxorubicin-induced cardiotoxicity: Role of caveolin-1 upregulation and enhanced autophagic response. Nutrients. 2021;13(11):4070–83.CrossRef

Title: Icariin synergizes therapeutic effect of dexamethasone on adriamycin-induced nephrotic syndrome
Authors: Juan Lv
Guozhong Xue
Yunxia Zhang
Xinbin Wang
Enlai Dai
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Chloroquin
Chloroquin
Nephrotic Syndrome
Dexamethasone
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-022-00973-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Icariin synergizes therapeutic effect of dexamethasone on adriamycin-induced nephrotic syndrome

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Intravascular laser irradiation of blood as novel migraine treatment: an observational study

Pulmonary endarterectomy in patients with occlusive isolated pulmonary vasculitis

Mesenchymal stem cells-derived exosomes: novel carriers for nanoparticle to combat cancer

Factors assessed in the first year of a longitudinal study predict subsequent study visit compliance: the TEDDY study

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

Sleep disturbance increases the risk of severity and acquisition of COVID-19: a systematic review and meta-analysis